F10 and stroke disorder: To take a high-profile example, the New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) study was terminated early because of futility and excess bleeding on rivaroxaban [4].